-
Pfizer Agrees To Pay $93M To Settle Lipitor Antitrust Lawsuit Despite Calling Allegations 'Factually And Legally Without Merit'
Thursday, February 15, 2024 - 3:24am | 617Read More...Pfizer Inc (NYSE:PFE) has agreed to pay $93 million to settle an antitrust lawsuit related to its cholesterol drug Lipitor. What Happened: The lawsuit, filed by wholesale drug distributors, accused Pfizer of colluding with India’s Ranbaxy Laboratories to delay the sale of cheaper, generic...
-
Pfizer Tanks on Earnings, Unhealthy Guidance
Tuesday, April 30, 2013 - 10:36am | 446Read More...Pfizer (NYSE: PFE) is down Tuesday after reporting woeful first-quarter earnings and lowering its guidance. The New York City-based firm's EPS rose 58 percent to $0.38, but fell far short of the $0.56 Wall Street consensus. Revenue fell over nine percent to $13.5 billion, missing the $14...
-
Pfizer Posts Strong Profits, Faces Strong Headwinds
Tuesday, July 31, 2012 - 9:51am | 349Read More...Pfizer (NYSE: PFE) reported second quarter earnings that beat analyst estimates. However, with the loss of Lipitor exclusivity and Viagra next to go, the future remains challenging. Pfizer's net income increased in the quarter, jumping 25 percent to $3.25 billion from $2.61 billion a year ago....
-
ImmunoCellular's Intellectual Property Steadily Increases
Wednesday, March 28, 2012 - 10:43pm | 1662Read More...Warner-Lambert’s 1996 approval for Lipitor paved the way for the company’s future as it was key to the company sealing its February 2000 $90 billion merger agreement with Pfizer (NYSE: PFE). Sales of the blockbuster drug were phenomenal and proceeds helped pay for the next decade of...
-
JP Morgan: Teva Benefitting from Ranbaxy Exclusivity
Thursday, December 1, 2011 - 11:24am | 114Read More...In a published report, JP Morgan says Teva Pharmaceutical (NASDAQ: TEVA) is expected to benefit from the generic Lipitor situation, as the company is announced to receive a potion of profits during period of exclusivity. JPM says, “While terms of the agreement with Ranbaxy are undisclosed...
-
How to Play It: Pfizer's Lipitor to Go Generic At The End of Month
Monday, November 7, 2011 - 5:14pm | 647Read More...On November 30, Pfizer's (NYSE: PFE) blockbuster drug Lipitor will face generic competition. Lipitor, a cholesterol drug, is the best selling drug of all time. An Indian company called Ranbaxy Laboratories will begin selling a generic version of the drug (atorvastatin) at the end of the month after...
-
One Pill Makes You Stronger: Pfizer Earnings Are the "White Knight"
Tuesday, November 1, 2011 - 11:53am | 896Read More..."One pill makes you stronger, and the other makes you small." -"White Knight", Jefferson Airplane With Pfizer's earnings, you are looking for the pills to make you significantly stronger, with shares are up around 2% amidst a broadly weaker market today. Pfizer (NYSE: PFE), the New York-based...
-
Has Star Scientific Found A Cure For Alzheimer's Disease? (CIGX)
Tuesday, March 1, 2011 - 12:45pm | 404Read More...If Star Scientific's (NASDAQ: CIGX) press release is to be believed, we might be on the precipice of a genuine breakthrough. James Altucher took a moment to translate the confusing and unusually written press release into what he calls “Investor-English.” His conclusion is that Star Scientific has...
-
Citigroup Releases Pfizer Core Product Trends; Explains Price Target
Tuesday, October 26, 2010 - 7:41am | 143Read More...Citigroup has released its Pfizer, Inc. (NYSE: PFE) core product trends for the week ending 10/15/2010. Lipitor, Lyrica, Chantix and AriceptXR are among the drugs featured in the report. “We arrive at our $17 target price for Pfizer based on a relative P/E compared to the US Drug peer group,”...
-
Pfizer's Product Trends For The Week Ending 9/24
Wednesday, October 6, 2010 - 7:41am | 348Read More...Citigroup has issued a report on Pfizer's (NYSE: PFE) product trends for the week ending on 9/24. In the report, Citigroup writes "Lipitor NRx/TRx Share Was 21.5%(-5bps)/22.0%(-15bps). Lipitor YOY TRx's have declined -12% YTD. PFE took 5% & 6.9% price increases(PI's) on 7/1/10 & 1/1/10...
